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The  causative  agent  of human  tuberculosis,  Mycobacterium  tuberculosis  complex  (MTBC),  comprises  seven
phylogenetically  distinct  lineages  associated  with  different  geographical  regions.  Here we  review  the  lat-
est ﬁndings  on  the nature  and  amount  of genomic  diversity  within  and  between  MTBC  lineages.  We then
review  recent  evidence  for  the  effect  of this  genomic  diversity  on mycobacterial  phenotypes  measured
experimentally  and  in  clinical  settings.  We  conclude  that overall,  the  most  geographically  widespreadransmission Lineage  2 (includes  Beijing)  and Lineage  4 (also  known  as Euro-American)  are more  virulent  than  other
lineages  that  are  more  geographically  restricted.  This  increased  virulence  is  associated  with  delayed  or
reduced pro-inﬂammatory  host  immune  responses,  greater  severity  of disease,  and  enhanced  transmis-
sion.  Future  work  should  focus  on  the interaction  between  MTBC  and  human  genetic  diversity,  as  well
as  on  the  environmental  factors  that  modulate  these  interactions.
©  2014  The  Authors.  Published  by Elsevier  Ltd.  This  is  an open  access  article  under  the  CC  BY-NC-SA. Introduction
Tuberculosis (TB) in humans is mostly caused by the mem-
ers of the Mycobacterium tuberculosis complex (MTBC) known
s Mycobacterium tuberculosis sensu stricto and Mycobacterium
fricanum. MTBC are gram-positive acid-fast bacteria transmitted
ia aerosols generated by patients with pulmonary TB. The out-
ome of TB infection and disease is highly variable: exposure to
TBC can be followed by rapid clearance through innate immu-
ity, direct development of active disease, or latent infection that
ay  or may  not re-activate up to several decades following initial
xposure. Active TB disease comprises a range of presentations,
ncluding classical pulmonary TB, and various forms of extrapul-
onary disease such as TB meningitis and miliary TB. Each of these
ifferent forms of TB feature a variety of symptoms that are associ-
ted with diverse host responses to the pathogen [1]. Traditionally,
he different outcomes of TB infection and disease have been
ttributed to host and environmental variables [2]. Various human
enetic determinants are known to inﬂuence the susceptibility to
B [3] (see also contributions by Meyer et al. and Bustamante et al.
o this special issue). Environmental factors such as overcrowding
nd poor ventilation increase exposure to infectious particles [4],
∗ Corresponding author at: Department of Medical Parasitology and Infection
iology, Swiss Tropical and Public Health Institute, Socinstrasse 57, 4051 Basel,
witzerland. Tel.: +41 61 284 8369.
E-mail address: Sebastien.Gagneux@unibas.ch (S. Gagneux).
ttp://dx.doi.org/10.1016/j.smim.2014.09.012
044-5323/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unlicense  (http://creativecommons.org/licenses/by-nc-sa/3.0/).
and implementing improved ventilation has been shown to reduce
MTBC transmission [5]. Increasingly however, it is becoming clear
that better knowledge of the bacterial determinants of virulence
and their interaction with host and environmental factors will
improve our understanding of the pathogenesis of TB [6].
Many experimental studies have provided evidence that clinical
strains of MTBC differ in virulence (reviewed in [7–9]). How-
ever, unlike many other pathogenic bacteria like Corynebacterium
diphtheriae, Escherichia coli O157:H7, Shigella dysenteriae, Vibrio
cholerae, and Salmonella typhi, MTBC lacks canonical virulence fac-
tors such as, e.g. toxins. Hence in TB, determining the effects
of strain-speciﬁc variation on infection and disease is challeng-
ing. Some of the limitations for discovering general patterns in
genotype–phenotype associations have been the lack of phylo-
genetically robust classiﬁcation systems for MTBC clinical strains
[10]. Furthermore, identifying genetic determinants of virulence
requires analytical methods that index genomic diversity in a
more comprehensive manner as opposed to mere “genotyping”.
During the past 5 years, advances in DNA sequencing technolo-
gies have made available many whole-genome sequences of MTBC
clinical strains from around the world [11]. This has led to a bet-
ter understanding of the global phylogenetic diversity of MTBC.
Many genotyping schemes have been developed for MTBC in the
past, (reviewed in [12]), but only comparative whole-genome
sequencing (WGS) provides the phylogenetically robust framework
for strain classiﬁcation coupled with the sensitivity required to
unmask the genetic particularities of different strains in detail.
In addition, DNA sequence information can be further exploited
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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sing various comparative genomic and population genetic tools
o predict the potential phenotypic impact of particular genetic
olymorphisms [13,14].
In this review, we start by describing the latest insights from
GS  data into the nature of MTBC genomic diversity, and provide
 list of new databases and analysis platforms for WGS  data relevant
o MTBC. We  then review recent attempts to predict the impact of
TBC genomic diversity on gene function and host immune recog-
ition. We  continue by summarizing the most recent experimental
nd epidemiological evidence supporting the relevance of MTBC
enomic diversity for different virulence phenotypes, and end with
n outlook on future research directions.
. The nature of MTBC genomic diversity
.1. Genotyping methods to classify MTBC clinical strains
During the last decades, various molecular techniques of DNA
ngerprinting have been used to discriminate between clinical
trains of MTBC (reviewed in [12]). Restriction fragment length
olymorphisms (RFLP) typing is based on differences in copy num-
er and the differential genomic location of the insertion sequence
IS) 6110, and became the ﬁrst gold standard method for geno-
yping MTBC [15]. This technique has been used successfully to
eﬁne chains of ongoing TB transmission, discriminate relapse
rom re-infection, and to detect laboratory cross-contaminations
16,17]. IS6110 is an IS element of 1361 bp ﬂanked by 28 bp inverted
epeats which is differently inserted in the genome across strains.
S6110-RFLP analysis relies on digestion of genomic DNA with
ndonucleases followed by electrophoretic separation, blotting
nto a nylon membrane, and probing of the restriction fragments
ith a IS6110-speciﬁc DNA fragment. Some of the limitations
f IS6110-RFLP are that this technique is difﬁcult to reproduce
etween laboratories, and that it requires large amounts of good
uality DNA.
Because of these limitations, several PCR-based methods
ave been developed for MTBC strain typing that require little
NA. These include spoligotyping and Mycobacterial Interspersed
epeat Units (MIRUs) typing, which together have been recently
eﬁned as the new gold standard for molecular epidemiologi-
al investigation of TB [12]. Spoligotyping patterns are deﬁned
ased on the presence or absence of 43 unique regions intercalated
etween direct repeats in the Clustered Regularly Interspaced Short
alindromic Repeats region (CRISPRs) of the MTBC genome. MIRU
roﬁles classify MTBC strains by the number of repeats at different
ariable Number of Tandem Repeats (VNTRs) loci. Spoligo-types
nd MIRU-types can be compared using the SITVITWEB database
hat includes thousands of spoligotyping patterns [18] and MIRU-
NTRplus [19]. However, the use of spoligotyping and MIRUs is
imited for phylogenetics and strain classiﬁcation because of the
ropensity of the corresponding molecular markers for convergent
volution; i.e. because these markers change rapidly, the same or
able 1
atabases and bioinformatics tools to explore MTBC genomic diversity.
Tool type Tool name Input genomic data Variation
Database Tuberculist H37Rv complete genome Protein i
annotati
Database/tools TBDB 9 complete genomes and
10 WGS
Genomic
and bibli
Database/tools Patrik 101 complete genomes
and 1899 WGS
Compara
data, me
Database/tools PolyTb 1500 WGS  SNPs, sm
Database/tools GMTV 1084 WGS  Clinical, 
Software SpolPred WGS:fastq Spoligot
Software SeqSphere Gene sequences Sequenc
Software KvarQ WGS:fastq SNPs: drmmunology 26 (2014) 431–444
similar patterns can emerge by chance in strains that are phyloge-
netically unrelated [10].
To get around this problem, genomic deletions, often referred
to as Regions of Difference (RDs) or Large Sequence Polymorphism
(LSPs) have been used as markers to classify groups of MTBC strains
into main phylogenetic lineages [20–24], and sub-lineages [25,26].
Although horizontal gene transfer between MTBC and Mycobac-
terium canettii has been detected [27], the population structure
within MTBC is largely clonal [2,20]. Because on-going horizon-
tal gene exchange is rare in MTBC, LSPs are essentially irreversible,
making them ideal phylogenetic markers for strain classiﬁcation.
Following the completion of the ﬁrst MTBC genomes [28–30],
comparative genomics identiﬁed sets of phylogenetically infor-
mative single nucleotide polymorphisms (SNPs) that were used
to establish various strain-typing methodologies [29,31–33]. In
addition, several groups have developed SNP-typing schemes
using multilocus sequencing analyses [34–36]. More recently,
accumulating WGS  data have led to the development of novel
SNP-typing methods that rely on a broader understanding of the
global MTBC phylogenetic diversity [11]. Some of these methods
have been built into highly multiplexed assays [37–40]. In addition
to SNPs, other forms of genetic diversity have been incorporated
in high-throughput genotyping schemes, including spoligotyping
data [41,42], and drug resistance-conferring mutations [43].
2.2. New software and databases to explore genomic MTBC
diversity from WGS  data
Despite the usefulness of the various genotyping assays dis-
cussed above [11], WGS  remains the only tool that can classify
MTBC strains robustly, and simultaneously index genomic diver-
sity at all levels, be it at the level of whole populations [44,45],
within large outbreaks [46,47], during household transmission
[48], within single patients [49,50], or during in vitro evolution
[51–54]. Moreover, DNA sequence data can be used to measure
phylogenetic distances, and hence quantify the amount of genetic
diversity within and between groups of strains. Finally, WGS
allows discovering new mutations in particular strains, or groups
of strains, associated with particular phenotypes. While WGS  is
becoming cheaper and more widely available, the analysis of WGS
data remains often limiting. Hence, rapid and user-friendly analysis
methods are required. Recently, several new databases have been
developed that make WGS  data readily available. These platforms
also include tools to visualize and analyze MTBC genomic diversity
(Table 1). They contain multiple types of information on multiple
MTBC genomes, including DNA and protein sequences, maps,
assemblies, annotations, and bibliography, as well as gene expres-
sion and protein data associated with different genomic regions.
While the Tuberculist database [55] offers diverse information
on the reference M.  tuberculosis genome of the laboratory strain
H37Rv, these new databases incorporate tools for comparative
 investigated Reference
nformation, drug and transcriptome data, mutant and operon
on, bibliography, structural views and comparative genomics
[55]
 (SNPs, small indels), expression (RNA-seq and microarrays)
ography.
[228]
tive genomics of mycobacteria, annotations, access to WGS
tadata associated with genomes.
[229]
all indels and large deletions. [230]
epidemiological, microbiological and genome variations [231]
yping [56]
e types [232]
ug resistant and phylogenetic markers [57]
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enomics, and include data from various MTBC clinical strains as
ell as other species within the genus Mycobacterium (Table 1).
ost of these databases build on already available genomes.
n addition, new tools have been developed recently that help
xplore unknown genomic diversity based on newly generated
GS  data. For example, SpolPred predicts the spoligo-type from
hort DNA sequencing reads [56]. Similarly, KvarQ provides a
obust SNP typing schemes using short DNA sequencing reads
rom WGS, and offers a robust classiﬁcation in the main human-
nd animal-adapted lineages of MTBC. In addition, KvarQ identiﬁes
rug resistance-conferring mutations [57]. In summary, recent
dvances in WGS  of MTBC clinical strains are revealing a larger
mount of between-strain genomic diversity than generally appre-
iated (see below). Increasingly, it is also becoming clear that this
enomic diversity translates into relevant phenotypic variation.
.3. Differences between MTBC strains and lineages
The MTBC comprises various closely related bacterial species
nd sub-species, including M.  tuberculosis sensu stricto and M.
fricanum which are adapted to humans, as well as several animal-
dapted forms [58], i.e. M.  bovis, M.  caprae,  M.  microti, M. pinnipedii,
.  origys,  M.  mungi,  M.  suricattae,  the dassie bacillus, and the chim-
anzee bacillus [59–62]. In addition to these classical members of
TBC, the Complex also comprises more distantly related bacte-
ia known as M.  canettii and other so-called “smooth tuberculosis
acilli (STBs)”, which are characterized by a smooth colony mor-
hology (STB) [63–65]. The STBs exhibit several other important
eatures, including strong evidence of horizontal gene transfer,
hich sets them apart from the other members of MTBC [66]. Only
pproximately 60 isolates of STB have been described so far, most of
hich from the Horn of Africa. Increasing epidemiological evidence
uggests STBs are environmental organisms that only occasionally
nfect humans [67].
One of the ﬁrst evolutionary reconstructions of the genetic
opulation structure of the whole MTBC highlighted a group of
trains harbouring a deletion in the genomic region known as TbD1
68]. TbD1-deleted strains have been referred to as evolutionar-
ly “modern” compared to the strains without this deletion, which
ollectively have been referred to as evolutionarily “ancestral” or
ancient”. Today, based on WGS  analyses, we know that MTBC com-
rises seven human-adapted lineages (Lineages 1–7 in Fig. 1A),
here the “modern” clade form a monophyletic group comprising
he TbD1-deleted Lineages 2, 3 and 4, as these lineages diversiﬁed
ore recently than the remaining MTBC strains. By contrast, the
ancestral” strains are paraphyletic, meaning they do not comprise
 single phylogenetic group. Many studies have shown that the
uman-adapted MTBC lineages show a strong phylogeographical
opulation structure, with the different lineages associated with
istinct geographical regions [20,24,33–35,69,70]. Some of these
ineages are also more globally widespread than others (Fig. 1).
peciﬁcally, the most widely distributed groups are Lineages 2 and
 (Fig. 1B). Lineage 2 (also known as East-Asian lineage, includes
he Beijing family of strains) predominates in East Asia, but is also
resent in Central Asia, Russia and South-Africa. Lineage 4 (also
nown as the Euro-American lineage) occurs frequently in popula-
ions from Asia, Europe, Africa and America. Lineages 1 and 3 show
 more restricted geographical distribution limited to East Africa,
entral-, South- and South-East Asia (Fig. 1C). The most geograph-
cally restricted lineages are Lineages 5–7, which are all associated
ith speciﬁc regions of Africa (Fig. 1D). Lineages 5 and 6 are also
nown as M.  africanum West Africa 1 and West Africa 2, respec-
ively, and almost exclusively occur in West Africa or in recent
mmigrants from those regions [71]. Lineage 6 occurs primarily in
he Western part of West Africa, whereas Lineage 5 dominates fur-
her to the East in regions bordering the Gulf of Guinea [71,72].mmunology 26 (2014) 431–444 433
Similarly, the recently discovered Lineage 7 is conﬁned to Ethiopia
and recent immigrants from that part of the world. The reasons for
why these three lineages are limited to speciﬁc regions of Africa
are unknown [73,74]. Finally, two  other lineages within the classi-
cal MTBC are adapted to different wild or domestic animal species
(Fig. 1A). One of these two  lineages comprises the classical animal-
associated strains M. bovis (includes the vaccine strains BCG), M.
caprae, M. microti,  M.  pinnipedii and M. orygis.  The other animal-
adapted lineage includes the chimpanzee bacillus, and, although
genome data are not yet available, likely also the dassie bacillus, M.
mungi and M. suricatae [59–62]. Recently, a new group of MTBC
has been identiﬁed in 1000-year-old human remains from Peru
[75]. These ancient MTBC strains were distinct from any known
human-adapted MTBC, but most closely related to contemporary
M. pinnipedii which is adapted to seals and sea lions. These ﬁndings
suggest that marine mammals could have played a role in spread-
ing TB from Africa across the Atlantic Ocean to the New World and
transmitting to pre-Columbian human populations [75], Fig. 1A).
For the remainder of this review, we  will focus on the classical
human-adapted members of MTBC, i.e. the Lineages 1–7 depicted
in colour in Fig. 1.
Strains of MTBC differ in their content of SNPs, small insertion
and deletions (indels), large genomic deletions, large duplications
and insertion sequences. Unlike MIRU and spoligotyping patterns,
LSP are robust makers for phylogenetic classiﬁcation, but LSPs are
not polymorphic enough to differentiate among closely related
strains, e.g. within an outbreak or transmission chain. By contrast,
WGS reveals all types of mutations, and provides the best discrim-
inatory power to differentiate between strains. Moreover, WGS
allows computing phylogenetic distances and quantifying genomic
diversity within and between groups of strains. To obtain an initial
estimate of within MTBC diversity, we  have used previously pub-
lished whole genome sequences of 217 globally distributed clinical
strains [76] and calculated the number of SNPs between any pair
of strains. On average, two  human-adapted MTBC strains differed
by about 1200 SNPs, which corresponds to 0.03% of the genome
when excluding repetitive sequences (Fig. 2). By contrast, the cor-
responding difference between any classical MTBC strain and M.
canettii was  about 2.7% [65], which is 90 times larger than the
average SNP-distance among human-adapted members of MTBC.
Next, we  calculated the average SNP distances within and between
human-adapted MTBC lineages (Fig. 2). The geographical origin of
strains included in this analysis was  diverse, and except for Lineage
7 that is only found in Ethiopia and Ethiopian immigrants, every
lineage included strains from various countries. We found that Lin-
eage 1 harboured the largest genetic diversity with an average of
730 SNPs between any two strains belonging to this lineage. The
corresponding average distance was  lowest for Lineage 7 with only
230 SNPs. In terms of between lineage diversity, the strains belong-
ing to the “modern” Lineages 2–4 differed by 970 SNPs in average.
Strains belonging to the “ancestral” Lineages 1, 5, and 6 were more
distantly related with an average of 1500 SNPs between them. The
maximum SNP distance of 1800 SNPs was  observed between strains
of Lineage 7 and either Lineage 1, 5, or 6 (Fig. 2). Although these
estimates might change when more genomes are considered, they
provide a ﬁrst indication of the relative genomic distances within
and between the different human-adapted lineages of MTBC.
3. The consequences of genomic diversity in MTBC
3.1. Predictions of the impact of MTBC genomic diversityIn addition to exploring and quantifying the genomic diversity
in MTBC, WGS  data has been used together with computational
methods to predict the impact of this variation on the bacterial
phenotype. One of the striking observations has been that contrary
434 M. Coscolla, S. Gagneux / Seminars in Immunology 26 (2014) 431–444
Fig. 1. (A) Maximum likelihood phylogeny modiﬁed from Bos et al. [75]. Node support after 1000 bootstrap replications is shown on branches and the tree is rooted by the
outgroup M. canettii. Large Sequence Polymorphisms (LSPs) described in [68] are indicated along branches. Scale bar indicates the number of nucleotide substitutions per
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eographically widespread lineages, panel (C) the intermediately distributed lineag
o many other organisms, in MTBC about two thirds of SNPs in
oding regions are non-synonymous (i.e. amino acid changing)
29,35,76,77]. Moreover, using sequence data from 89 genes in 107
TBC strains, Hershberg et al. [35] observed that 58% of the non-
ynonymous mutations fell in positions that were highly conserved
n other mycobacteria, suggesting that most of these mutations in
TBC might have functional consequences. More recently, Rose
t al. used WGS  data to identify all SNPs speciﬁc to the different
uman-adapted lineages of MTBC; these are SNPs that are ﬁxed in
he corresponding bacterial populations [78] (Fig. 3A). The number
f ﬁxed SNPs (i.e. synonymous and non-synonymous) ranged from
24 in Lineage 2 to 698 in Lineage 5, but in all cases, at least 44% of
he non-synonymous SNPs ﬁxed in one or the other lineage were
redicted to impact gene function (Fig. 3B). Taken together, these
ndings illustrate that even though the overall genomic diversity of
TBC is low compared to other bacteria [79], a large proportion of
he mutations that have accumulated in the different phylogenetic
ineages of MTBC are likely to lead to phenotypic differences.
An alternative way to predict the functional consequences of
utations is to determine the evolutionary conservation of the
orresponding genomic regions and the selection pressures in
esponse to which these mutations evolve. The importance of a pro-
ein residue is reﬂected in its evolutionary conservation [80]. For
xample, loci coding for important general functions will be under
urifying selection and thus highly conserved. Alternatively, func-
ional innovations might be under positive selection, and hence
etecting positively selected sites in genomes can point to adaptives represented in the 875 MTBC strains from the global strain collection analyzed by
d the extinct MTBC strains from Peru, respectively [75]: panel (B) shows the most
d panel (D) the most geographically restricted lineages.
processes. One of the strongest on-going selection pressures in
MTBC has been drug pressure, and detection of positive selection
has been used successfully to identify molecular markers of drug
resistance [81–83]. One particular signature of positive selection
is the independent multiple appearance of the same mutation; a
phenomenon referred to as convergent evolution. Convergent evo-
lution leading to so-called homoplasies are generally uncommon
in MTBC, except for mutations involved in drug resistance [52].
Recently, signatures of positive selection have also been detected in
membrane proteins of MTBC, suggesting a role of the correspond-
ing mutations in the interaction with the host immune system
[83].
WGS  data can also be used to explore the putative impact of
host recognition in MTBC. Many pathogens evade host immunity by
means of antigenic variation [84]. Intriguingly, a comparative WGS
analysis of 21 MTBC clinical strains from global sources revealed
that the majority of 495 experimentally conﬁrmed human T-cell
epitopes in these strains were highly conserved [77]. The conser-
vation of T-cell epitopes in human-adapted MTBC might reﬂect the
fact that the host immune response is largely responsible for the
lung damage during TB disease (i.e. cavitation), which increases
patient coughing and hence contributes the successful transmis-
sion of the pathogen. Indeed, TB patients with cavitary disease
are more likely to generate secondary cases [85]. These ﬁndings
have implications for the development of new TB vaccines and
diagnostics, as highly conserved antigens might represent ideal
diagnostic targets, but not adequate vaccine components if the
M.  Coscolla, S. Gagneux / Seminars in Immunology 26 (2014) 431–444 435
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mmune responses they elicit beneﬁt the bacteria rather than the
ost.
.2. The phenotypic consequences of genomic variation
Four years ago, we reviewed the available experimental and epi-
emiological evidence for strain-speciﬁc phenotypic diversity [7].
ince then, additional studies have come out providing additional
upport for the view that strain variation in MTBC has important
henotypic consequences. Different MTBC strains and lineages dif-
er in their growth rates in liquid culture [86,87], in monocyte
erived macrophages [87], and in mice [88,89]. MTBC strains and
ineages also differ in their gene expression [78,88] and metabolic
roﬁles [90]. A recent clustering analysis derived from the differ-
ntial use of various substrates separated strains according to three
ajor lineages [90]. Most recently, Portevin et al. reported signif-
cant differences in mycolic acid proﬁles between different MTBC
trains and lineages [91]. Mycolic acids constitute the most abun-
ant cell wall lipid in MTBC, and play an important role in the host
mmune response [92]. They also help the bacteria resist oxidative
tress [93].
One of the challenges in studying the effect of MTBC strain varia-
ion has been linking genotype to phenotype. As mentioned above,
 wide range of mutations occur across MTBC genomes includ-
ng SNPs, deletion, duplications and mobile elements, all of which
an have an impact on bacterial phenotypes. In the next few para-
raphs, we review recent studies that have managed to link a given
utation in MTBC clinical strains to a particular phenotype.
.2.1. Single nucleotide polymorphisms
SNPs are natural polymorphism that can be classiﬁed as
ynonymous, non-synonymous, nonsense, or intergenic. Because
on-synonymous SNPs change the amino acid content of the corre-
ponding protein, they are the principal contributors to functional
utations. A special category of SNPs which are better referred
o as (de novo) single nucleotide mutations occur in genes asso-
iated with resistance to anti-TB drugs. These mutations decrease
he susceptibility to a particular drug by either modifying the drug-
arget, increasing the expression of the gene product targeted by
he drug, or by reducing the drug activation in the case of pro-
rugs [94,95]. Other non-synonymous SNPs have been shown to
mpact on the MTBC phenotype irrespective of drug resistance, with
he PhoPR two-component system providing a particularly illus-
rative example. The PhoPR components are essential for MTBC
irulence in animal models of TB (reviewed in [96]), and several
oint mutations in either component of this system have been
hown to lead to important changes in bacterial phenotype. For
xample, one amino acid change at position 219 of PhoP in the lab-
ratory strain H37Ra alters the binding capacity of PhoP to its own
romotor [97]. As a result, H37Ra is highly attenuated compared to
ts virulent counterpart H37Rv. Similarly, one amino acid change
t position 71 of PhoR occurs naturally in all MTBC strains belong-
ng to Lineages 5 and 6, and in all animal-adapted MTBC strains.
his mutation was shown to affect the PhoPR regulatory system,
nd consequently, the synthesis of important surface lipids and
he secretion of the 6-kDa antigenic target ESAT-6 were reduced
n the corresponding strains [98]. Non-synonymous SNPs can also
ead to epigenetic changes. Recently, Shell et al. described one non-
ynonymous SNP in the methiltransferase mamA in Lineage 2 and
nother non-synonymous SNP in the active site of hsdM in Lineage
 that lead to variation in adenine methylation levels in strains
elonging to these lineages [99].Compared to non-synonymous SNPs, intergenic and synony-
ous SNPs are often referred to as evolutionary neutral because
n average, their effect on phenotype, and hence ﬁtness, is less.
owever, some synonymous SNPs do have important phenotypicmmunology 26 (2014) 431–444
effects. For example, a synonymous SNP within the gene immedi-
ately upstream of DosR has been shown to generate an alternative
internal transcriptional start site (TSS) in Lineage 2/Beijing strains.
This TSS has been associated with increased expression of the dosR
regulon [78]. Similarly, a synonymous SNP upstream of malQ in
Lineage 1 strains has been found to create a new TSS associated
with increased expression of malQ [78]. Finally, a recent study
reported a synonymous SNP leading to a new internal TSS in mabA
which was demonstrated to confer isoniazid resistance in MTBC
clinical strains, representing a novel mechanism of resistance to
this important ﬁrst line anti-TB drug [100]. Additionally, SNPs in
non-coding regions can have important functional consequences.
Non-coding SNPs in promoter regions can modify the promoters
and therefore alter transcriptional regulation. For example, several
intergenic SNPs in the promoter of the inhA gene, increase the tran-
scription level of inhA, thereby conferring resistance to isoniazid
and ethionomide [101,102].
Finally, nonsense mutations result in a premature stop codon
that produce truncated peptides with a likely impact on the func-
tionality of the product encoded; this process is also referred to
as pseudogenization. Unlike M. leprae where almost half of the
coding DNA sequences are pseudo-genes [103], pseudogenization
in MTBC seem to be a more recent process and not as signiﬁ-
cant as in M. leprae [104]. However, some nonsense mutations are
found within MTBC, where Lineage 6 and the M.  bovis clades con-
tain more pseudo-genes than other lineages [104]. Many of these
nonsense mutations are in genes that have analogous genes or
pathways in the MTBC genome and presumably, these mutations
will have a minor phenotypic impact due to genomic redundancy
[104].
3.2.2. Gene duplications
Gene duplications and the expansion of gene families are impor-
tant sources of genetic diversity with the potential to lead to
evolutionary innovations [105]. Duplications of the ESAT-6 gene
clusters in an ancestor of MTBC resulted in the expansion of the
PE/PPE gene family [106]. PE/PPE genes have been postulated to
play a role in antigenic variation [107–109]. Indeed, these genes are
highly polymorphic [110–114], but the evolutionary forces driv-
ing this diversity remain unknown. Nevertheless, differences in
nucleotide variation and gene expression in some PE/PPE genes
have been associated with virulence [115,116].
Although there is currently no evidence of large duplications
being a major source of genomic diversity within MTBC, sev-
eral instances have been reported. A 350 kb genomic duplication
that includes the DosR operon has been observed in some Lin-
eage 2 strains. This duplication has been suggested to be partially
responsible for increased expression of the dosR regulon in Lineage
2/Beijing strains discussed above [117]. However, this duplication
is not seen in all Lineage 2/Beijing strains [78], possibly because
the duplicated regions are lost during in vitro cultivation [117].
Interestingly, in addition to some Lineage 2 strains, some strains
belonging to Lineage 4 have been shown to carry independent
duplications spanning the same genomic region [118]. As outlined
before, the presence of convergent evolution events in MTBC is rare
[52]. Therefore, the convergent duplication of dosR regulon might
indicate some evolutionary advantage of strains harbouring this
duplication.
Large scale duplications might also have played a role during the
in vitro evolution of BCG strains. Two tandem duplications termed
DU1 and DU2, of 29,668 bp and 36,161 bp, respectively, are present
in M. bovis BCG Pasteur compared to H37Rv [119]. Intriguingly, DU2
showed four alternative forms evolved in the different laboratories
where the different BCG strains were passaged, leading to indepen-
dent duplications of similar genomic regions [120]. If and how these
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uplications impact BCG phenotypes, including vaccine efﬁcacy,
emains unknown [54].
.2.3. Repetitive and mobile genetic elements
Repetitive elements such as CRISPs, VNTRs and ISs have been
sed as molecular markers for MTBC strain genotyping (discussed
bove and reviewed in [12]). These elements are an important
ource of genomic variation that could impact bacterial pheno-
ypes.
The CRISPR region in MTBC is known to be polymorphic and
hows convergent deletions in phylogenetically unrelated strains
121]. However, the functional role (if any) of polymorphisms
ffecting to the CRISPR region in MTBC, or the impact of CRISPR
olymorphisms on mycobacterial phenotypes have not been deter-
ined.
In humans, variation in some VNTR loci is associated with com-
lex diseases such as type-1 diabetes [122]. In bacteria, VNTRs have
een implicated in the ON/OFF switching of phase variable genes
n Neisseria [123,124]. In mycobacteria, intragenic VNTR loci vari-
tion has been shown to modify the structure and function of the
roteins affected [125]. Intergenic VNTR variation can alter pro-
oter activity in downstream genes [126–128]. For example, an
ncreased number of repeats in the VNTR3239 locus of MTBC leads
o a higher expression of the downstream gene fpg1, a DNA gly-
osylase shown to be involved in the protection against oxidative
NA damage [126].
Finally, differential insertion of the IS6110 sequences in MTBC
linical strains has been shown to lead to important phenotypic
ffects linked to changes in gene expression. When inserted in
he upstream region of a gene, the insertion sequence can modify
he transcription of neighbouring genes by acting as a promo-
or [129–131]. In addition, insertion of IS6110 can disrupt genes.
ndeed, the presence of independent disruptions of the same gene
n different clinical strains, i.e. another example of convergent evo-
ution, might be associated with an evolutionary advantage for the
orresponding strains [132]. For example, one hyper-virulent M.
ovis strains that caused an outbreak of human TB in Spain showed
n IS6110 insertion upstream of the phoP regulon [98]. The expres-
ion of the phoP regulon is generally diminished in animal strains
nd Lineage 6 strains due to the non-synonymous SNP in phoP men-
ioned above. The insertion of IS6110 upstream of phoP regulon
n this hyper-virulent M.  bovis restores phoP transcription, com-
ensating for the effect of the non-synonymous SNP [98]. M. bovis
s generally not an efﬁcient pathogen in humans, among which
t rarely transmits. However, this single IS6110 insertion seemed
o have transformed an MTBC strain adapted to cattle into a vari-
nt capable of sustaining a transmission cycle in a new host (i.e.
umans).
.2.4. Genomic deletions
Large genomic deletions are a substantial source of genomic
iversity within MTBC. Genomic deletions can result from transpo-
ition of mobile genetic elements, like in the case of the prophages
hiRv1 (linked to RD3) and phiRv2 (linked to RD11), and insertion
equences IS1532 (e.g. in the case of RD6) or IS6110 (e.g. in the case
f RD5) [68,133]. Deletions can also be mediated by homologous
ecombination between adjacent IS6110 resulting in the loss of the
ntervening DNA segment; examples for this mechanism include
vD2, RvD3, RvD4, and RvD5 [68]. In addition, many genomic dele-
ions occur through unknown mechanisms [23].
Deletion of one or several loci can greatly inﬂuence the bacterial
henotype. One of the most relevant MTBC phenotype is drug
esistance, and deletions have been implicated in drug resistance
henotypes. The presence of repetitive sequences near the katG
egion of the M.  tuberculosis genome makes this gene prone tommunology 26 (2014) 431–444 437
deletions [134], and deletions of katG have been shown to confer
high level resistance to isoniazid [135].
Other deletions have been reported to lead to the modiﬁca-
tion of the lipid composition of the mycobacterial wall, which can
therefore alter the bacterial interaction with host cells. A dele-
tion disrupting the locus of the polyketide synthase (Pks)15/1 in
strains belonging to Lineage 4 results in a defective production
of phenolic glycolipid (PGL) [136], thereby affecting the bacterial
interaction with host immune cells [137]. Indeed, the absence of
PGL has been linked to reduced MTBC virulence in infection mod-
els [138,139]. Similarly, a deletion speciﬁc to all Lineage 3 strains
involves Rv1519, and has been linked to a decrease in the produc-
tion of the anti-inﬂammatory cytokine IL-10 by in infected hosts
[140]. Genomic deletions have also been associated with clinical
phenotypes. For example, patients with extra-pulmonary TB were
more likely to carry MTBC strains with a deletion in the phospholi-
pase C-encoding gene plcD [141]. Moreover, a deletion of the embR
locus has been detected in a particularly successful multidrug-
resistant strain of MTBC that has successfully spread between
continents (Coscolla et al., submitted for publication). EmbR is a
transcriptional regulator implicated in ethambutol resistance, as
well as in the regulation of lipomannan/lipoarabinomannan ratio
[142], which serves as immunomodulator crucial for mycobacterial
virulence (reviewed in [143]). Finally, deletions in PE PGRS33 have
been associated with reduced induction of tumour necrosis factor-
 (TNF-)  by the host [144], reduced patient clustering (indicating
reduced transmission), and absence of lung cavitation, supporting
the view that PE PGRS33 plays a role in the transmission success of
MTBC in clinical settings [145].
3.3. New evidence supporting differences in virulence and
immunogenicity between MTBC clinical strains
Following the 100 studies we  reviewed 4 years ago [7], many
new studies have explored the effect of MTBC strain variation
on virulence and immunogenicity. Human-adapted MTBC is an
obligate pathogen in the sense that (i) it has no other animal or envi-
ronmental reservoir and (ii) it has to cause (pulmonary) disease to
transmit successfully. In other words, virulence is directly linked
to transmission [85,146], which is unlike many other pathogens
where transmission occurs independently of disease. “Virulence” in
TB can be conceptualized as a composite comprising (i) the ability
of the bacteria to survive in face of the host immune responses, (ii)
their capacity to cause lung damage, (iii) to survive the aerosoliza-
tion process outside of the host, and (iv) successfully transmit to
and infect a new host. In the following sections, we  review recent
studies that have generated evidence supporting strain differences
with regards to these individual components of “virulence”.
3.3.1. Impact on host immune regulation
Studies in humans and animal models have shown that TNF-,
interferon-gamma (IFN-), IL-12 and IL-17 are important medi-
ators of a protective immune response against TB (reviewed in
[1,147]). Other mediators such as IL-10 may  play a role in limiting
MTBC clearance during the early immune response [148]. Consid-
ering the link between virulence and transmissibility in MTBC, one
could postulate that a more severe inﬂammatory response causing
more lung damage would lead to more efﬁcient transmission (fur-
ther discussed in [147]). Intriguingly however, many studies have
found increased MTBC virulence associated with reduced and/or
delayed inﬂammatory responses, perhaps by allowing a stronger
bacterial proliferation early during the infection process, leading
to increased virulence at a later stage. For example, studies in
different infection models have found strain NH878 (belongs to Lin-
eage 2/Beijing) constantly associated with a delayed inﬂammatory
immune response and increased virulence [149–156].
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At the lineage level, the so-called “modern” Lineages 2–4,
howed a lower early inﬂammatory response compared to Lin-
ages 1 and 6 [157]. As discussed under Section 2.3, “modern”
TBC strains are more globally wide-spread than other lineages.
ence, the observation that “modern” strains are associated with
 delayed inﬂammatory response (i.e. higher virulence) might be
inked to the global success of these strains [6]. Indeed, a study by
eiling et al. [158] showed that “modern” strains were replicating
aster in vitro, in human monocyte-derived macrophages, as well as
n aerosol-infected mice. Several other studies have demonstrated
he reduced/delayed pro-inﬂammatory response of the “modern”
ersus other lineages [159]. By contrast, Krishnan et al. [89] showed
ncreased inﬂammatory responses in Lineage 1 strains compared to
ineage 4, but these were not signiﬁcantly higher than in Lineage
 strains.
Other studies have compared the different lineages within
modern” lineages. One study found that Lineage 3 exhibited
 higher anti-inﬂammatory phenotype compared to Lineage 4
140,160,161]. Wang et al. [162] reported that different Lineage
/Beijing strains commonly induced lower levels of TNF-, IL-6,
L-10 and GRO- compared to strain H37Rv in monocyte-derived
acrophages and dendritic cells. Similarly, Sarkar et al. [87]
howed that Lineage 2 exhibited a lower pro-inﬂammatory pheno-
ype compared to Lineages 3 and 4. Some studies however, showed
he contrary, Lineage 4 eliciting more TNF- than Lineage 2; this
as particularly true when compared to a sub-lineage of Lineage 2
nown as “modern Beijing” [163]. Moreover, Krishnan et al. [89] did
ot detect any differences between Lineages 2 and 4. These contra-
ictory ﬁndings with respect to the host immune responses elicited
y Lineages 2 and 4 could on the one hand be due to differences in
xperimental conditions. On the other hand, sub-lineages within
he main lineages, as well as individual strains within any given
ineage might vary in the inﬂammatory responses they elicit.
Because the main MTBC lineages are not genetically homoge-
eous (Fig. 2), differences in immune regulation among strains are
xpected at sub-lineage level [157]. Such differences have been
ost widely studied in Lineage 2, where “modern Beijing” showed
 lower inﬂammatory response compared to so-called “ancient Bei-
ing” [159,163]. Yet, Wang et al. [162] did not ﬁnd any differences
etween Beijing strains. Some of the variable cytokine proﬁles
licited by the distinct groups of strains within Lineage 2 have
een linked to differential toll-like receptor recognition [164]. Only
ne study has investigated intra-lineage variation within Lineage 4
ut found no difference between the so-called H and T families of
trains [160].
Increased “virulence” surely entails more than a mere delay
n early pro-inﬂammatory response. Indeed, Reiling et al. [158]
eported lineage-speciﬁc differences in virulence proﬁles based
n variable bacterial uptake by host cells, differences in cytokine
nduction, and intracellular growth. In agreement with other
tudies, the “modern” Lineages 2 and 4 showed high replicative
otential compared to “ancestral” Lineages 1 and 6. However,
ineage 2 was characterized by low uptake, and low cytokine induc-
ion, whereas Lineages 1 and 4 exhibited high uptake and higher
ytokine induction.
To date, few studies have combined host and bacterial factors
hen studying the different immune response during MTBC infec-
ions in humans. Coussens et al. [165] showed that ethnicity plays
n important role in the different inﬂammatory proﬁles in Africans
ersus Eurasians from a population in London, while MTBC lineages
id not contributed signiﬁcantly to the different immune responses
n this patient population..3.2. Impact on disease severity
An alternative way of measuring “virulence” is to look at the
everity of the disease. Stavrum et al. [166] showed that TB patientsmmunology 26 (2014) 431–444
from Tanzania infected with “modern” Lineage 4 strains showed
more 1-acid glycoprotein and C reactive protein, higher neu-
trophils counts, and a lower body mass index than those infected
with Lineage 1. De Jong et al. [167] showed that in the Gambia, indi-
viduals infected with modern Lineages 2 and 4 were more likely to
progress to active disease compared to individuals infected with
Lineage 6. The higher virulence of the modern Lineage 2 com-
pared to “ancient” Lineage 6 was corroborated in a novel marmoset
model of infection [168]. Infection with Lineage 2 induced more
rapid weight loss, and led to a higher bacterial load in liver, spleen
and lymph nodes [168]. Finally, several studies have found Lineage
2 associated with relapse [169–171], treatment failure [172], and
fever early during treatment [173].
Within the “modern” lineages, Lineage 2 is generally associ-
ated with higher “virulence” than Lineage 4. For example, Orgarkov
et al. [174] found that patients carrying a polymorphism previ-
ously associated with TB (CD209 336 A/G) who  were infected with
Lineage 2 were more likely to die of TB compared to patients
infected with other strains. Nahid et al. [175] found during a clinical
trial that patients infected with Lineage 2 strains and one sub-
group of Lineage 4 were more likely to yield a positive culture at
week 8 after treatment initiation when compared to other Lineage
4 strains.
Similar to the observed differences in immune responses caused
by different sub-lineages described above, within-lineage differ-
ences in disease presentation have also been reported. Kato-Maeda
et al. [176] reported that a group of highly transmissible Lin-
eage 2 strains from San Francisco were more virulent than other
Lineage 2 strains in guinea pigs. Likewise, Aguilar et al. [177]
demonstrated that highly transmissible Lineage 2/Beijing sub-
lineages from South Africa were more virulent in mice than less
transmissible strains. Taken together, the observation that highly
transmissible strains tend to cause more severe disease in ani-
mal  models is consistent with intrinsic bacterial features linking
“virulence” with pathogenicity, transmission, and overall strain
ﬁtness.
3.3.3. Impact on disease presentation
Besides the classical pulmonary presentation, MTBC can cause
a wide variety of extra-pulmonary manifestations affecting many
organs of the human body [178]. Pulmonary and extra-pulmonary
TB can also occur simultaneously. Because efﬁcient MTBC trans-
mission relies on lung damage, bacterial genotypes that are more
prone to cause pulmonary and cavitary disease will be able to trans-
mit  more efﬁciently. Experiments in the marmoset model have
revealed more extra-pulmonary spread to the lymph node, liver
and spleen in animals infected with a Lineage 6 clinical strain com-
pared to animals infected with the Lineage 4 strain CDC1551 [168].
Importantly, these experiments were conducted using genetically
identical individuals (i.e. marmosets always give birth to twins or
triplets), suggesting that the different disease presentation associ-
ated with the different MTBC strains are due to strain rather host
genetic differences.
In humans, epidemiological studies have been rather incon-
sistent with regards to MTBC strain or lineage effects on disease
presentations. At least ﬁve studies have reported such effects.
Kong et al. reported an associating between Lineage 2 and extra-
pulmonary TB [179,180]. Another study found a similar association
when comparing Lineage 2 to Lineages 3 and 4 [181]. By contrast,
Click et al. found Lineages 1 and 3 associated with extra-pulmonaryLineage 4 associated with pulmonary rather than meningeal TB
[183]. On the other hand, at least ﬁve studies failed to ﬁnd
any association between MTBC lineage and disease presentation
[74,173,184–186].
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.3.4. Impact on transmission
Rates of MTBC transmission are generally inferred by comparing
enotypic clustering between patient isolates from a given epi-
emiological setting [187]. Another proxy for inferring successful
ransmission of particular MTBC genotypes is measuring increases
n the frequency of these genotypes over time in patient popula-
ions. Finally, genotypes associated with younger patient age have
lso been interpreted as reﬂecting successful transmission, because
B in young patients are more likely to reﬂect ongoing transmission
s opposed to reactivation [188].
Based on these concepts, several epidemiological studies have
upported the view that overall, strains from “modern” lineages
re more transmissible than other MTBC strains. Buu et al. [189]
eported higher genotypic clustering of Lineage 2 compared Lin-
age 1 in Vietnam. Similarly, a study in Shanghai found Lineage
 associated with higher clustering and younger age compared to
ther strains [190]. Many other studies in various settings have
eported a higher ﬁtness of Lineage 2/Beijing strains reﬂected by
ncreases in their frequency over time [69,159,191–196]. In some
ases, the increase of Lineage 2 was associated with drug resis-
ance [189,197]. Yet, several studies observed no such increase and
o enhanced transmissibility of Lineage 2 strains [167,198–201].
ome of these contradictory ﬁndings could be due to differences
n the study populations. For example Marais et al. [200] did not
nd any association between Lineage 2 and higher transmission
mong children of South Africa. Alternatively, if sub-lineages differ
n transmissibility, the genetic heterogeneity within lineages would
ead to inconsistent results among different study settings where
ub-lineages differ in prevalence. In support of this notion, Kato-
aeda et al. showed that one sub-lineage within Lineage 2 showed
igher genotypic clustering in San Francisco [202]. This sub-lineage
as also more virulent in guinea pigs, supporting again an intrin-
ic bacterial role in increased pathogenicity linked to enhanced
ransmission [176]. Sub-lineages of other lineages also tend to dif-
er in their transmissibility as observed in San Francisco, USA for
ineage 4 [203] and Cotonu, Benin for Lineage 5 [72]. However,
hree studies have reported decreasing prevalence of M. africanum
i.e. Lineages 5 and 6) in Cameroon, Guinea-Bissau and Burkina
aso [204–206], supporting of the lower “virulence” of the “ances-
ral” lineages. Therefore, although sub-lineage differences might
bscure general patterns, taken together, these studies support the
iew that on average “modern” MTBC lineages are more transmis-
ible than other strains. Yet, Albanna et al. [199] observed reduced
ransmissibility of “modern” Lineage 3 compared to other lineages
n Montreal, albeit with no difference between Lineages 1, 2 and 4.
. Conclusions
MTBC has for many years been regarded as a “clone”, har-
ouring too little genetic diversity to be worth considering. This
aradigm has now changed, and many experimental and epidemi-
logical studies have demonstrated the phenotypic impact of MTBC
train diversity. During the last 4 years alone, at least 52 new
tudies have explored phenotypic differences among strains and
ineages of MTBC, in addition to the 100 studies we reviewed ear-
ier [7]. Although clinical studies have reported discordant results
egarding the propensity of MTBC lineages to cause pulmonary
s opposed to extra-pulmonary disease, studies focusing on other
roxies of “virulence” have detected common patterns showing
hat “modern” lineages are generally more virulent and more glob-
lly successful, compared to other more geographically restricted
ineages (Fig. 1). Differences in immunogenicity, severity of dis-
ase, and transmission consistently indicate that Lineages 2 and 4
re more virulent than Lineages 1 and 6. More work is needed with
espect to Lineages 3, 5 and 7, but given the restricted geographi-
al distribution of these latter lineages (Fig. 1), chances are that atmmunology 26 (2014) 431–444 439
least Lineages 5 and 7 will prove to be low virulence variants. Con-
sistent with previous reports [8,207], many studies have noticed
an emergence of Lineage 2/Beijing over time. This increase of Lin-
eage 2/Beijing might be partially driven by environmental factors
such as antibiotic treatment (reviewed in [208]) or BCG vaccination
[209–211]. In addition, this effect could also be driven by changes in
host demography. Speciﬁcally, the human population expansions
during the Neolithic- and Industrial Revolutions have been hypo-
thetically linked to an increase in virulence of some MTBC lineages
[6,75,76].
5. Outlook
In this review, we primarily focused on the genetic diver-
sity of MTBC, i.e. the pathogen. As discussed in the contributions
by Meyer et al. and Bustamante et al. to this special issue,
human genetic variation plays an important role in TB. Consid-
ering the long-term association between MTBC and its human
host [212], some degree of co-evolution is likely to have occurred
[20,24,33–35,69,70,213,214]. Indeed, several recent studies have
shown that the susceptibility to TB is inﬂuenced by variation in
both the pathogen and the host [183,215–217]. Hence, the inter-
actions between host and pathogen genomic diversity needs to be
explored and better understood using novel approaches [218,219].
Moreover, the various environmental variables modulating these
interactions will have to be considered [2]. A particular challenge
will be predicting phenotypes or evolutionary responses in the con-
text of changing environments [220]. MTBC faces many different
environmental conditions during its life cycle. These are encoun-
tered when penetrating into host cells, surviving within granuloma
and cavities, persisting during aerosol transmission, and resist-
ing drug pressure. Recently, a new environment has emerged to
which MTBC has to adapt to: HIV co-infection [221]. Epidemiolog-
ical studies have reported associations between HIV and Lineage
2 [222–224] and Lineage 6 in co-infected TB patients [225]. But
how HIV co-infection as a selective pressure might impact the evo-
lutionary trajectory of MTBC on the long run is unclear [146]. All
of these complexities call for integrated approaches based on sys-
tems biology [226] and systems epidemiology [6] to improve our
understanding of the role of variation in the host, the pathogen,
and the environment in TB. Such an improved understanding will
likely pave the way for novel tools and strategies to better control
this important disease.
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